# Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

> **NCT00644696** · PHASE1 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Irinotecan and Bortezomib

## Key facts

- **NCT ID:** NCT00644696
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644696, "Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00644696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*